SCHEMBL29334102

SCHEMBL29334102

COC(=O)c1cc(Br)cc2nccn12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.40
ALDH1A1 P00352 4/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HSD17B10 Q99714 2/20 0.40
HPGD P15428 1/20 0.40
FBP1 P09467 1/20 0.40
NOTUM Q6P988 1/20 0.35
JMJD6 Q6NYC1 1/20 0.34
HSP90AA1 P07900 1/20 0.34
HSP90B1 P14625 1/20 0.34
TSHR P16473 2/20 0.33
PPARG P37231 1/20 0.33
MAPK10 P53779 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
NCOR2 Q9Y618 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19697629 0.84 ALDH1A1 (0.42) KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD
SCHEMBL19697437 0.83 KDM4E (0.41) KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD
SCHEMBL19697817 0.83 KDM4E (0.43) KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD
SCHEMBL2048286 0.78 RAB9A (0.42) KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD
SCHEMBL19697838 0.75 CYP4A11 (0.43) KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD
SCHEMBL16388000 0.75 CDK8 (0.42) KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD
SCHEMBL21291152 0.74 KDM4E (0.35) KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD
SCHEMBL19697833 0.74 KDM4E (0.35) KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD
SCHEMBL21875420 0.74 EGLN2 (0.44) KDM4EALDH1A1HSD17B10HPGDNOTUM
SCHEMBL19697724 0.73 KDM4E (0.34) KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4594308-A1 N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF Vividion Therapeutics, Inc. (US) 2025-08-06 EP disclosed
US-20240226114-A1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2024-07-11 US disclosed
US-20240226114-A1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2024-07-11 US disclosed
US-20240226114-A1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2024-07-11 US disclosed
WO-2024073587-A1 N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2024-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226114-A1 INHIBITORS AND USES THEREOF KEAP1, NQO1, NFE2L2 KDM4E 1830/4885ALDH1A1 1020/4885SMN1; SMN2 3374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.